Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

People are interested in trying clascosterone (Breezula) for hair loss, especially those who are too young for finasteride. Some users express concerns about the cost and prescription requirements, while others discuss alternatives like RU58841.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The user wants to mix 0.2 ml of RU58841 solution with 2 ml of Alfatradiol to use 10 mg of RU58841 daily due to concerns about side effects. They are asking if this combination would be effective for hair loss treatment.

Pyrilutamide from RUdirect is discussed, with users sharing experiences and alternative sources like Koshinemall. Users mention using treatments like minoxidil, RU58841, and dutasteride for hair loss.

The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

GHK-Cu is discussed for hair loss treatment, with some users reporting positive results using a 4% topical serum, but concerns exist about the long-term safety of oral or injectable forms. The original poster also uses finasteride and plans to start dutasteride.

The conversation is about a user concerned about a prescribed 5 mL daily dose of 5% minoxidil for seborrheic dermatitis and hair thinning, which seems excessive compared to the typical 2 mL recommendation. The user is advised to consult their dermatologist and consider additional treatments like ketoconazole and CBD+MCT.

The user experienced no significant improvement in hair loss despite using Dutasteride, oral Minoxidil, and previously RU58841, and is uncertain if changes in medication or stopping RU58841 worsened the condition. Some users noted no change or slight improvement, while others suggested the possibility of Dutasteride causing issues.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

A 27-year-old has seen hair regrowth over 5 months using 2ml of 5% minoxidil daily, 50mg of RU58841 daily, and occasional microneedling. Commenters think the results are good and ask about microneedling frequency, needle size, and if ketoconazole shampoo is used.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

The user is using Dutasteride 0.5 mg, Minoxidil 5%, and Microneedling for almost 5 months to address hair loss. They are considering a hair transplant for the front and crown areas due to thinning and a high hairline.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.